Skip to Main Content

Paper Details

A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic.
J Pharmacol Exp Ther
4
2021
Coronavirus Disease, SARS-, SARS-CoV-2, chronic lower respiratory diseases, coronavirus, coronavirus 2, human, malignant neoplasms, metabolic disorders, neurodegenerative diseases, severe acute respiratory syndrome, severe acute respiratory syndrome coronavirus, viral DNA, viral genome
Author NameAffiliation
Joseph P MenetskiPfizer Inc., V.S.V.) Foundation for the National Institutes of Health, Massachusetts (R.I.T.) and Brigham and Women's Hospital, Harvard Medical School
Elliott M AntmanPfizer Inc., V.S.V.) Foundation for the National Institutes of Health, Massachusetts (R.I.T.) and Brigham and Women's Hospital, Harvard Medical School
  • 1 - 2

Datasets

Release 1.2